

Table SI. Clinical trials of anti-IL-6/IL-6R combining immunotherapy in lung cancer.

Target molecule	Phase	Therapeutic approach	NCT no.
IL-6/IL-6R	2	Ipilimumab, nivolumab, tocilizumab	NCT04940299
	1-2	Atezolizumab, tocilizumab	NCT04691817
	1-2	Atezolizumab, cobimetinib, RO6958688, docetaxel, CPI444, pemetrexed, carboplatin, gemcitabine, linagliptin, tocilizumab, ipatasertib, bevacizumab, sacituzumab govitecan, radiation, evolocumab	NCT03337698